MoonLake Immunotherapeutics (MLTX)
| Market Cap | 2.89B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.77M |
| Shares Out | 63.06M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 650,784 |
| Open | 44.39 |
| Previous Close | 43.81 |
| Day's Range | 44.10 - 47.02 |
| 52-Week Range | 37.55 - 64.98 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 84.20 (+83.76%) |
| Earnings Date | Feb 27, 2025 |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MLTX stock is "Strong Buy." The 12-month stock price forecast is $84.2, which is an increase of 83.76% from the latest price.
News
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon
MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies using sonelokimab to target moderate-to-severe Hidradenitis Suppurativa patients in mid-2025. The ...
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulos...
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stag...
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 20...
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, Moon...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program...
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company focused on nanobody development with its drug Sonelokimab. Sonelokimab has shown positive results in clinical trials for psoriasis, hid...
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing t...
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for H...
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody ® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology C...
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody ® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatolog...
MoonLake Immunotherapeutics Is Now Thoroughly De-Risked
MoonLake Immunotherapeutics has seen success in the last 5 months after positive data from a phase 2 trial of sonelokimab in hidradenitis suppurativa. Sonelokimab has shown promising results in treati...
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
MoonLake Immunotherapeutics to ho st a Capital Markets Day on Monday , September 11
Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)
MoonLake Immunotherapeutics' financial health improved with $501.8M cash reserves and robust Q2 2023 research advancements. MLTX focuses on sonelokimab's potential in treating HS, collaborating with S...
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
ZUG, Switzerland, August 10, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflamm...
August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains ...
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts